A changing time: The International Society for Cellular Therapy embraces its industry members

Robert Deans, Kurt C. Gunter, Timothy Allsopp, Mark Bonyhadi, Scott R. Burger, Melissa Carpenter, Tara Clark, Charles S. Cox, Dawn Driscoll, Ed Field, Ralf Huss, René Lardenoije, Tracey A. Lodie, Chris Mason, Richard Neubiser, John E.J. Rasko, Jon Rowley, Richard T. Maziarz

Research output: Contribution to journalEditorial

3 Scopus citations

Abstract

The last decade has seen a dramatic rise in the development of new cellular therapeutics in a wide range of indications. There have been acceptable safety profiles reported in early studies using blood-derived and adherent stem cell products, but also an inconsistent efficacy record. Further expansion has been hindered in part by a lack of capital (both private and public) and delayed entry into the cell therapy space by large healthcare and pharmaceutical companies, those members of the industry most reliably able to initiate and maintain advanced-phase clinical trials. With recognition that the International Society for Cellular Therapy (ISCT) is uniquely positioned to serve the global translational regenerative medicine research community as a network hub for scientific standards and policy, the ISCT commissioned the establishment of an Industry Task Force (ITF) to address current and future roles for industry. The objectives of the ITF were to gather information and prioritize efforts for a new Commercialization Committee (CC) and to construct innovative platforms that would foster constructive and synergistic collaborations between industry and ISCT. Recommendations and conclusions of the ITF included that the new CC: (1) foster new relationships with therapeutic and stem cell societies, (2) foster educational workshops and forums to cross-educate and standardize practices, (3) create industry subcommittees to address priority initiatives, with clear benchmarks and global implementation, and (4) establish a framework for a greater industry community within ISCT, opening doors for industry to share the new vision for commercialization of cell therapy, emphasizing the regenerative medicine space.

Original languageEnglish (US)
Pages (from-to)853-856
Number of pages4
JournalCytotherapy
Volume12
Issue number7
DOIs
StatePublished - Nov 2010

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Genetics(clinical)
  • Cell Biology
  • Cancer Research
  • Transplantation

Fingerprint Dive into the research topics of 'A changing time: The International Society for Cellular Therapy embraces its industry members'. Together they form a unique fingerprint.

  • Cite this

    Deans, R., Gunter, K. C., Allsopp, T., Bonyhadi, M., Burger, S. R., Carpenter, M., Clark, T., Cox, C. S., Driscoll, D., Field, E., Huss, R., Lardenoije, R., Lodie, T. A., Mason, C., Neubiser, R., Rasko, J. E. J., Rowley, J., & Maziarz, R. T. (2010). A changing time: The International Society for Cellular Therapy embraces its industry members. Cytotherapy, 12(7), 853-856. https://doi.org/10.3109/14653249.2010.523958